New calcium pill could ease burden for hypoparathyroidism patients

NCT ID NCT06547151

Ongoing Disease control Sponsor: Amorphical Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 4 times

Summary

This study tests a new form of calcium called AMOR-1 in 81 adults with hypoparathyroidism, a condition where the body can't control calcium levels. Participants will take either AMOR-1 or standard calcium pills to see if AMOR-1 can better maintain normal calcium levels while allowing them to take less calcium overall. The trial is double-blind, meaning neither patients nor doctors know who gets which treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Amorphous Calcium Carbonate (AMOR-1)
What this could lead to: If successful, this could offer a more effective way to manage calcium levels in people with hypoparathyroidism, potentially reducing the need for high-dose calcium supplements.
What could go wrong: This is an early Phase 2 trial with only 81 participants, so results may not apply to everyone. The treatment may not work better than standard calcium, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hypocalcemia hypoparathyroidism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPOPARATHYROIDISM

Contacts and locations

Locations

Assuta Ashdod medical center

Ashdod, Israel, Israel
Barzilai Medical Center

Ashkelon, Israel
Hadassah Ein Kerem Medical Center

Jerusalem, Israel, Israel
Kaplan Medical Center

Rehovot, Israel
Lin Medical Center

Haifa, Israel, Israel
Rabin Medical Center, Belinson Campus

Petah Tikva, Israel, 49100, Israel
Rambam Medical Center

Haifa, Israel
Sheba Medical Center

Ramat Gan, Israel
Soroka Medical Center

Beersheba, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.